Cardiometabolic Health Congress

Cardiometabolic Health Congress

Source:

Healio Interviews

Disclosures: Ballantyne receives research support paid to his institution from Abbott Diagnostics, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Regeneron and Roche Diagnostics; and is a consultant for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostics and Sanofi-Synthelabo.
October 13, 2021
2 min read
Save

CMHC to spotlight cardiometabolic disease, ‘the health care problem of our century’

Source:

Healio Interviews

Disclosures: Ballantyne receives research support paid to his institution from Abbott Diagnostics, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Regeneron and Roche Diagnostics; and is a consultant for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostics and Sanofi-Synthelabo.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Cardiologists, endocrinologists and primary care physicians will convene both virtually and in-person in National Harbor, Maryland, for the 2021 Cardiometabolic Health Congress.

In its 16th year, the Cardiometabolic Health Congress (CMHC) will take place from Oct. 14 to 17 and highlight the crossroads of cardiometabolic care and social determinants of health.

Source: Adobe Stock

The event will feature 4 days of research highlights, FDA updates, clinical insights and more.

Christie M. Ballantyne

“The biggest health threat to not only the U.S., but to the world, is cardiometabolic disease. There has been a tremendous increase in our country in obesity. With obesity comes hypertension, diabetes, CVD, atherosclerotic CVD, HF, sleep apnea, polycystic ovary syndrome and many other things that are also associated with chronic kidney disease,” Christie M. Ballantyne, MD, FNLA, professor of medicine, molecular and human genetics and molecular physiology and biophysics; director of the Maria and Alando J. Ballantyne, M.D. Atherosclerosis Clinical Research Laboratory; director of the Center for Cardiometabolic Disease Prevention; co-director of the Lipid Metabolism and Atherosclerosis Clinic; the J. S. Abercrombie Chair in Atherosclerosis and Lipoprotein Research; and chief of cardiology and cardiovascular research at Baylor College of Medicine, told Healio. “This is the health care problem of our century. During the pandemic, the individuals most likely to be hospitalized and die from COVID-19 were individuals with cardiometabolic disease. And it's not just COVID-19. They're also more likely to have problems with influenza and other infections. We have one multidisciplinary meeting where we bring together experts in all these fields to get the audience up to the state of the art in terms of management of patients with these problems.”

The first day of CMHC will begin with a preconference titled “A Wolf in Sheep's Clothing: Actionable Cardiometabolic Rare Diseases You Might Miss,” which will include overviews on rare lipid, CV, obesity and diabetes disorders, with expert panels, audience Q&As and case presentations.

“We see so many people with cardiometabolic disorders and we forget that some may have rarer, more severe problems,” Ballantyne told Healio. “As we move into precision medicine and sequencing becomes available for lower and lower costs, it's important we expand our knowledge about these individuals.”

The main program on the second day will kick off with opening remarks from Ballantyne as well as an FDA update and presentations about late-breaking clinical trials from experts including Keith C. Ferdinand, MD, Robert H. Eckel, MD, Anne L. Peters, MD, Deepak L. Bhatt, MD, MPH, and George L. Bakris, MD.

The second day will also include a keynote address presented by Sandeep Jauhar, MD, advanced heart failure transplant cardiologist at Northwell Health, titled “The Emotional Heart,” during which Jauhar will discuss they ways in which psychological wellbeing can impact CV and cardiometabolic risk.

The remainder of the meeting will be comprised of four sessions, covering various topics in cardiometabolic health:

  • Friday, Oct. 15 will feature “Session I: Obesity and Lifestyle.”
  • Saturday, Oct. 16 will feature “Session II: Dyslipidemia/Atherosclerosis/Thrombosis” and “Session III: Diabetes.”
  • Sunday, Oct. 16 will feature “Session III: Hypertension/HF/Kidney.”

“Here, you get focused sessions on diabetes, obesity, hypertension and hyperlipidemia, and you don't have to go to four different meetings, you go to one meeting,” Ballantyne told Healio. “You have a chance to hear experts and to hear cases; you get an update on the newest guidelines; and also a review and refresher. I'm an expert in my area, but every year I attend CMHC, I'm learning something new from the speakers, and sometimes I'm relearning something I may have forgotten.”

Healio will be providing the latest news from CMHC, with researcher interviews and clinician insight that can be read here.

Reference: